2015
DOI: 10.1016/j.nutres.2015.05.012
|View full text |Cite
|
Sign up to set email alerts
|

d-Xylose suppresses adipogenesis and regulates lipid metabolism genes in high-fat diet–induced obese mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
31
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 39 publications
(32 citation statements)
references
References 60 publications
(66 reference statements)
0
31
1
Order By: Relevance
“…This was supported by the fact that PPARα, ACO and CPT I all play a crucial role in FAs oxidation, which provides energy for peripheral tissues (Lefebvre, Chinetti, Fruchart, & Staels, ; Rigamonti, Chinetti‐Gbaguidi, & Staels, ). Generally, when an animal is in a lipid‐overloaded state, and lipids are metabolically dysregulated, the β‐oxidation of fatty acids in peroxisomal, mitochondrial and microsomal is usually suppressed, thus leading to hepatic steatosis (Lim et al., ). Taken together, these results might imply that XOS supplementation inhibits hepatic fat accumulation by regulating mitochondrial, peroxisomal and microsomal fatty acid oxidation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This was supported by the fact that PPARα, ACO and CPT I all play a crucial role in FAs oxidation, which provides energy for peripheral tissues (Lefebvre, Chinetti, Fruchart, & Staels, ; Rigamonti, Chinetti‐Gbaguidi, & Staels, ). Generally, when an animal is in a lipid‐overloaded state, and lipids are metabolically dysregulated, the β‐oxidation of fatty acids in peroxisomal, mitochondrial and microsomal is usually suppressed, thus leading to hepatic steatosis (Lim et al., ). Taken together, these results might imply that XOS supplementation inhibits hepatic fat accumulation by regulating mitochondrial, peroxisomal and microsomal fatty acid oxidation.…”
Section: Discussionmentioning
confidence: 99%
“…This was supported by the facts that (i) LPL, being the rate‐limiting enzyme for the hydrolysis of core triglycerides, promotes the cellular uptake of cholesterol‐rich lipoproteins and free fatty acids (Nilsson‐Ehle, Garfinkel, & Schotz, ) and (ii) CD36 regulates protein whose expression is modulated by conditions that alter lipid metabolism (Brinkmann, Abumrad, Ibrahimi, Vandervusse, & Glatz, ). Generally, the up‐regulation of LPL and the down‐regulation of CD36 could lead to steatosis (Lim et al., ). In fact, the increase in CD36 mRNA levels observed in this study was associated with the decreased plasma levels of NEFAs, TG, TC and LDL, as well as the increased HDL levels of fish fed HFD supplemented with 10 g/kg and 20 g/kg XOS which were similar to those fed the control diet.…”
Section: Discussionmentioning
confidence: 99%
“…d -Xylose is a natural pentose and a potent sucrose inhibitor [44]. A recent study showed that the administration of 5% or 10% d -xylose in sucrose mixtures significantly lowered blood glucose levels in humans [45].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, administration of 10% d -xylose in a sucrose solution significantly reduced under the glucose curve (AUCg) values and under the insulin curve (AUCi) values obtained from OGTTs performed for healthy individuals [46]. Improved lipid metabolism in serum and gene expression in adipose and liver tissues following administration of D-xylose have also been investigated in an animal model [44]. …”
Section: Discussionmentioning
confidence: 99%
“…Thus, it becomes the 'nondigestible' (ND) dietary carbohydrate substrates (Cummings and Macfarlane, 1991). It has been reported that d-xylose is beneficial for the alleviation of adipogenesis and dyslipidemia in obese mice (Lim et al, 2015), and it is difficult to be digested by species of bacteria from the human colon (Louis et al, 2007). Xylose can be used as a substitute for table sugar for obesity patients.…”
Section: Introductionmentioning
confidence: 99%